tirzepatide cvot Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Original Article: Cardiovascular Outcomes with
Pay in 4 interest-free payments of $6.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



























